title: Tivozanib: a novel VGFR inhibitor for kidney cancer.
abstract: Treatment of kidney cancer has changed over the past 10 years with the approval of several targeted agents. These drugs are given on a long term base and toxicity is an issue for most patients. Despite improvement compared to immunotherapy, most patients will progress on these drugs. There is a need for more portent and better tolerated drugs. Tivozanib is a potent pan VEGR specific inhibitor. In this phase II trial it gave interesting results with an overall median PFS throughout the study of 11.7 months (95% CI: 8.3-14.3 months) and an overall objective response rate of 24% (95% CI: 19-30%). "Off"-target toxicity was mild.
authors.affiliation: Medical Oncology Department, Centre Léon Bérard, 28 rue Laënnec, 69373 Lyon cedex 08, France.
authors.forename: Helen
authors.initials: H
authors.lastname: Boyle
keywords: Tivozanib; VGFR inhibitor; kidney cancer
references.citation: N Engl J Med. 2007 Jan 11;356(2):115-24
references.pmid: 17215529
references.citation: J Clin Oncol. 2012 May 10;30(14):1678-85
references.pmid: 22493422
references.citation: J Clin Oncol. 2013 Oct 20;31(30):3791-9
references.pmid: 24019545
references.citation: Lancet. 2011 Dec 3;378(9807):1931-9
references.pmid: 22056247
references.citation: J Clin Oncol. 2009 Jul 10;27(20):3312-8
references.pmid: 19451442
references.citation: J Clin Oncol. 2010 Feb 20;28(6):1061-8
references.pmid: 20100962
references.citation: Clin Cancer Res. 2006 Dec 15;12 (24):7215-20
references.pmid: 17189392
references.citation: J Clin Oncol. 2009 Aug 1;27(22):3584-90
references.pmid: 19487381